The impact of comorbidities in patients with spondyloarthritis

Hou, Xiaofeng; Lee, Yung‐Heng; Qian, Tangliang; Chen, Connie; Tam, Lai‐Shan

doi:10.1111/1756-185x.14682

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study investigated the rates of uveitis recurrence and new-onset occurrence among patients with AS receiving TNFα inhibitors and examined whether there were differences among three different TNFi agents. Understanding the impact of TNFi treatment on uveitis is crucial in patients with AS, as uveitis, a common extra-articular manifestation of AS, can significantly affect patients' quality of life [20][21][22], and TNFi treatment is widely used for AS. Our study showed that, during the first two years of therapy, the incidence of new-onset AU was significantly higher in patients treated with etanercept than in those treated with adalimumab.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors

Kwon,

Kim,

Kim

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Anterior uveitis (AU) is a significant concern in patients with ankylosing spondylitis (AS), and the choice of tumor necrosis factor inhibitors (TNFi) as a treatment modality raises questions regarding its effects on AU. We compared the effects of TNFi on AU in patients with AS. Methods: Patients diagnosed with AS and treated with at least one TNFi, including anti-TNFα antibodies (adalimumab and infliximab) or a soluble TNF receptor molecule (etanercept), between January 2010 and December 2022, were retrospectively reviewed. We compared the recurrence rate of AU in patients with a history of uveitis and the incidence of new-onset AU in those without a history of uveitis among the three TNFi groups. We also compared the effects of two different TNFi agents in patients who underwent TNFi switching. Results: Within two years of treatment initiation, there was no significant difference in AU recurrence among the three TNFi groups. However, the incidence of new-onset AU was significantly higher in the etanercept group than in the adalimumab group (26.4% vs. 6.3%; p = 0.024). After two years, the AU recurrence rate was significantly lower in the adalimumab group than in the other groups (p < 0.001). Among patients who underwent anti-TNFi switching, adalimumab treatment was associated with a significantly lower incidence of uveitis than etanercept (p = 0.023). Conclusion: In the short-term period following TNFi therapy, etanercept induced new-onset AU more frequently than adalimumab in patients with AS. Adalimumab recipients experienced fewer AU recurrences during the subsequent long-term period compared to other TNFi recipients.

show abstract

Section: Discussionmentioning

confidence: 99%